Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 8/13/19 → 1/2/25 |
Funding
- Exelixis Inc.: $128,711.00
A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors
- Arnold, Susanne (PI)